• Zosano Pharma (ZSAN) Pivotal Trial Results of ZP-Triptan for Migraine

       (0 reviews)

    Biotech_Forecast
    Clinical and Regulatory
    Event Type: Phase 1 Results
    Timing: Q1 2017
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Neurology
    Indication: Migraine
    Lead Indication?: No
    Treatment Name: ZP-Triptan

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Zosano Pharma
    Stock Symbol: ZSAN
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://ir.zosanopharma.com/releasedetail.cfm?ReleaseID=970787
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

    Quote

    FREMONT, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage specialty pharmaceutical company with proprietary technology for the dermal delivery of drugs, today announced financial results for the first quarter ended March 31, 2016.

    "Zosano is making progress towards initiating our pivotal efficacy trial for our ZP-Triptan product candidate for the acute treatment of migraine. Completion of the pivotal study by Q1 2017 remains on target," said Dr. Konstantinos Alataris, Zosano's President and Chief Executive Officer

     

     


      Report Event


    User Feedback

    There are no reviews to display.